Sarepta, days out from critical FDA meeting, lists questions expected at gene therapy AdComm

Sarepta, days out from critical FDA meeting, lists questions expected at gene therapy AdComm

Source: 
Fierce Biotech
snippet: 

The clock is ticking down to the FDA advisory committee meeting about Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) gene therapy SRP-9001. With days to go, Sarepta has set out what is expected to be asked at the meeting—and made the case that it can allay concerns about its confirmatory trial.